The comparison between normal and neurological controls showed relatively pronounced increase in VEGF-A and CCL2 in the latter thus limiting the utility of these as biomarkers in ALS, however, further analysis of this data is being conducted by including homogeneous Parkinson's disease controls instead of the heterogeneous neurological controls used (data not shown). This evidence concerns the gene VEGFA and amyotrophic lateral sclerosis.